No published trial has dosed CJC-1295 and ipamorelin together in the same subjects and reported a combined amount or ratio. What the literature actually contains is two separate bodies of work: a human pharmacokinetic study of CJC-1295 with DAC reporting its own single- and multiple-amount design, and a preclinical ipamorelin pharmacology program reporting its own amount-response data in cells, rats and pigs. The ratios marketed on research combination vials are a commercial convention built from those two separate literatures, not a number taken from a joint study.
| Question | What the published record shows | Source |
|---|---|---|
| Has a combined CJC-1295 + ipamorelin amount or ratio been published? | No identified trial reports one; each molecule's amount-response data comes from a separate study | Teichman et al., 2006, PubMed 16352683; Raun et al., 1998, PubMed 9849822 |
| What CJC-1295 form was studied for amount and timing? | CJC-1295 with DAC (albumin-binding form), not the No DAC backbone sold in combination vials | Teichman et al., 2006 |
| Over what time frame was CJC-1295 tested? | Single-injection cohorts followed for several days, then a repeated-injection arm followed across roughly a month | Teichman et al., 2006 |
| What species supplied the ipamorelin amount-response data? | Isolated rat pituitary cells, then conscious rats and pigs | Raun et al., 1998 |
| Was a growth endpoint timed against ipamorelin amount in any study? | Yes, longitudinal bone growth rate in young rats measured against repeated daily administration | Johansen et al., 1999, PubMed 10373343 |
What amounts of CJC-1295 were studied in the published trial?
Teichman and colleagues ran their CJC-1295 with DAC program in two parts. The first part tested single subcutaneous injections across an ascending series of amounts in separate placebo-controlled cohorts of healthy adults, with the authors reporting a clear amount-response relationship in both the peak GH excursion and, more notably, in how long IGF-1 stayed above its pre-injection baseline afterward. The second part moved to repeated injections of two of the lower amounts from the first part, given on a once-weekly or twice-weekly interval across a study period of about a month, with GH and IGF-1 sampled throughout and for a period after the last injection. The authors' headline comparison was not peak hormone level but duration: a single CJC-1295 injection kept IGF-1 elevated for markedly longer than the minutes-to-hours window reported for unmodified GHRH(1-29) analogs, which the paper attributes to the albumin-binding chemistry rather than to the amount administered. That chemistry was characterized earlier by Jette and colleagues in rats, who showed the albumin-bound conjugate's plasma persistence came from the linkage itself rather than from a larger peptide amount. Exact microgram-per-kilogram figures from each cohort should be confirmed against the original trial report before being used in any downstream material; this article summarizes the design and relative comparisons rather than reproducing every cohort's number.
What amounts of ipamorelin have been studied?
Raun and colleagues reported ipamorelin's amount-response relationship across three settings: isolated rat pituitary cells exposed to a wide concentration range in culture medium, conscious rats given ipamorelin by injection across a series of amounts, and pigs tested the same way. In all three settings, GH release increased with amount up to a plateau, and the amounts needed to reach that plateau did not produce a comparable rise in cortisol, adrenocorticotropic hormone, prolactin or aldosterone, the comparison the authors used to support a selectivity claim for the ghrelin receptor over the pathways those other hormones depend on. Johansen and colleagues then tested repeated daily injections of ipamorelin in young rats, timed against growth-plate width and longitudinal bone growth rate measured over a period of weeks, and reported that higher amounts produced a larger increase in the growth rate up to the highest amount tested. Ipamorelin's amount data are not limited to animals: Gobburu and colleagues administered ipamorelin to human volunteers and modeled plasma concentration against the GH response, reporting a pharmacokinetic-pharmacodynamic relationship at the amounts tested, the closest the ipamorelin literature comes to a human amount-response dataset comparable to the Teichman CJC-1295 trial. As with the CJC-1295 figures, the exact numeric amounts used in each paper's dose-ranging design should be pulled from the original papers before being restated as fixed figures.
Is there a published ratio for combining CJC-1295 and ipamorelin?
No. A ratio implies a single study varied the relative amounts of two compounds against each other and reported an optimum; that design does not exist in the published CJC-1295 or ipamorelin literature discussed here. The commercial ratios seen on combination research vials, commonly built around a roughly equal split of the two peptides' own effective amount ranges, are a formulation choice rather than a cited trial outcome. The mechanistic case for pairing the two, laid out at cjc-1295-and-ipamorelin-in-combination-research, rests on the two receptors acting through separate pathways on the same somatotroph cell, which is a reasonable basis for a combination design but is not the same as a dose-finding trial of the combination itself.
How was timing of administration reported across the two literatures?
Timing is reported very differently in the two bodies of work. The CJC-1295 trial reports timing in days to weeks: a single injection's effect window measured in days, and a repeated-injection arm measured in weeks, both built around the slow clearance the DAC linkage produces. The ipamorelin pharmacology papers report timing in minutes to hours for the acute GH-release experiments in cells, rats and pigs, consistent with ipamorelin's shorter reported half-life, and in weeks for the separate bone-growth study, where the endpoint itself (growth-plate width) only changes meaningfully over an extended period of repeated administration. A vendor combination vial that pairs a long-clearance GHRH analog with a short-clearance ghrelin-receptor agonist is therefore pairing two different time courses, a point the published literature supports mechanistically even though it has not tested the pairing directly.
Why do these studies get described as "GH-pulse" research?
Growth hormone is not secreted at a constant rate; the pituitary releases it in discrete pulses, most prominently overnight, and both compounds discussed here were designed to act on that pulsatile pattern rather than to produce a flat, sustained elevation. Ipamorelin's acute GH-release experiments in cells, rats and pigs were built to characterize a single pulse: how much GH is released, how quickly, and how selectively relative to the other pituitary and adrenal hormones measured in the same samples. The CJC-1295 trial was built around a different question inside the same pulsatile framework: whether a single injection could extend the downstream consequence of a GH pulse, measured through IGF-1, well past the hour or two a pulse normally lasts. Reading the two papers side by side, the ipamorelin data describe the pulse itself and the CJC-1295 data describe how long the pulse's effect persists; neither paper reports what happens when the two are superimposed, which is the specific gap a combined ratio study would need to close.
What amount of CJC-1295 was needed in a genetic model lacking the GHRH receptor pathway?
Alba and colleagues tested CJC-1295 in mice engineered without a functional GHRH receptor. Once-daily administration at the amount reported in the paper restored a GH secretory pattern in these mice, a design that supports the GHRH-receptor mechanism rather than measuring an amount-response curve for its own sake. The relevance here is mechanistic rather than numeric: CJC-1295 needs a functioning GHRH receptor to work at all, while ipamorelin works through a separate receptor entirely, reinforcing why the two amount-response literatures have been kept apart.
Study data on amounts, route and timing as reported
| Study | Model and setting | Amount and route as reported | Endpoint | Finding |
|---|---|---|---|---|
| Teichman et al., 2006, PubMed 16352683 | Healthy adult volunteers, single-amount cohorts, placebo-controlled | Single subcutaneous injection, amount escalated across separate cohorts | Plasma GH and IGF-1 over several days | GH rose within hours; IGF-1 remained above baseline for multiple days, longer at higher amounts |
| Teichman et al., 2006 | Healthy adult volunteers, repeated-injection cohorts | Subcutaneous injections repeated on a once- or twice-weekly interval for about a month | Plasma GH, IGF-1, tolerability over the study period | IGF-1 stayed above baseline throughout dosing and for days after the final injection; reported as well tolerated |
| Raun et al., 1998, PubMed 9849822 | Isolated rat anterior pituitary cells (in vitro) | Added directly to the culture medium across a wide concentration range | GH released into the medium (immunoassay) | Dose-dependent GH release with potency comparable to GHRP-6 in the same assay |
| Raun et al., 1998 | Conscious rats (in vivo) | Injection across a series of amounts reported in the paper | GH, cortisol, ACTH, prolactin, aldosterone in blood | GH rose with amount; the other four hormones were not meaningfully changed at GH-maximal amounts |
| Raun et al., 1998 | Pigs (in vivo) | Injection across a series of amounts reported in the paper | GH and the same hormone panel as the rat arm | Selectivity pattern for GH over cortisol, ACTH, prolactin and aldosterone held across species |
| Johansen et al., 1999, PubMed 10373343 | Young male rats | Daily subcutaneous injection for a period of several weeks | Tibial growth plate width, longitudinal bone growth rate | Bone growth rate increased with amount, up to the highest amount tested in the study |
| Jette et al., 2005 | Rats (in vivo), albumin-conjugate pharmacology | Injection of the albumin-bound GRF(1-29) conjugate at amounts reported in the paper | Pituitary GHRH-receptor activation, plasma persistence of the conjugate | The conjugate activated the GHRH receptor and persisted in circulation far longer than unconjugated GRF(1-29) |
| Gobburu et al., 1999 | Human volunteers | Ipamorelin administered to volunteers at amounts reported in the paper; plasma sampled for pharmacokinetic modeling | Plasma ipamorelin concentration and GH response, modeled together | A pharmacokinetic-pharmacodynamic model linked plasma ipamorelin levels to the GH response at the amounts tested |
| Alba et al., 2006 | Mice with a non-functional GHRH receptor (genetic model) | Once-daily subcutaneous injection of CJC-1295 at the amount reported in the paper | GH secretory pattern | GH secretion was restored in the knockout mice, confirming the GHRH-receptor dependence of CJC-1295's mechanism |
How is this handled in a research setting?
Because the two peptides come from separate monotherapy literatures rather than a jointly studied combination, a research record for a blended vial should document the lot and concentration of each component separately rather than treating the vial as a single studied entity. Reconstitution math for two-peptide vials, including how to back-calculate each component's concentration from a labeled total, is covered at calculating-peptide-blend-concentrations and at reconstituting-lyophilized-peptides. Certificates of analysis for each component should be checked individually; what identity and purity data a certificate should carry is explained at how-to-read-a-peptide-coa. Lot-matched research vials of CJC-1295 (No DAC) plus ipamorelin, as well as standalone sermorelin and ipamorelin, ship with certificates that allow this kind of component-level bench record.
Frequently asked questions
Is the CJC-1295 in a combination vial the same form Teichman and colleagues studied?
Not necessarily. Teichman's trial studied CJC-1295 with DAC. Combination research vials typically use the No DAC backbone, which lacks the albumin-binding chemistry and has not been shown in a published pharmacokinetic study to produce the same multi-day effect window. The distinction is covered at cjc-1295-dac-vs-no-dac.
Why do vendors state a specific ratio if no trial tested it?
The ratio is a formulation decision based on each peptide's own reported effective amount range from its separate literature, not a figure taken from a trial that varied the ratio and measured an outcome.
Did the ipamorelin studies test the peptide in humans?
Most of the amount-response data summarized here comes from isolated rat pituitary cells, conscious rats and pigs. A separate human pharmacokinetic-pharmacodynamic study by Gobburu and colleagues administered ipamorelin to volunteers and modeled the resulting plasma levels against the GH response.
How long after one CJC-1295 injection did IGF-1 stay elevated in the published trial?
Teichman and colleagues reported IGF-1 remaining above baseline for multiple days after a single injection, with the exact duration varying by amount; the primary source should be consulted for the specific day-by-day figures.
Does a longer ipamorelin or CJC-1295 program change the amount-response relationship?
In the ipamorelin bone-growth study, repeated daily administration over several weeks was required before the growth-plate endpoint changed meaningfully; a single-timepoint hormone measurement would not have captured that effect.
Is there a published study comparing CJC-1295 No DAC directly against CJC-1295 with DAC at matched amounts?
Not among the papers reviewed here. The DAC-versus-No-DAC comparison in the literature is primarily a structural and half-life discussion rather than a head-to-head amount-matched trial.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed PMID 16352683.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed PMID 9849822.
- Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PubMed PMID 10373343.
- Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed PMID 9141536.
- Jette L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed PMID.
- Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed PMID.
- Alba M, Fintini D, Sagazio A, Hill CM, Rouque M, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth hormone secretion in mice with a targeted deletion of the GHRH receptor. J Clin Endocrinol Metab. 2006. PubMed PMID.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



